PTC Therapeutics Swings to Q3 2026 Net Loss of $51.69 Million From Year-Earlier Profit

Bitget2026/10/29 20:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

PTC Therapeutics swung to a third-quarter 2026 net loss of $51.69 million from year-earlier net income of $15.9 million.
Total revenue rose 70% year over year to $357.81 million, while product revenue more than doubled to $275.89 million.
Sephience revenue climbed 20% from the second quarter of 2026 to $181.9 million.
Newly acquired ST-920 Fabry disease therapy targets BLA submission completion in Q4 2026, with potential FDA accelerated approval in 2027.
Full-year 2026 revenue guidance increased to $1.29 billion–$1.32 billion, with product revenue projected at $960 million–$990 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610291601PR_NEWS_USPR_____NY85014) on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

PTC Therapeutics Swings to Q3 2026 Net Loss of $51.69 Million From Year-Earlier Profit

You may also like

Crypto prices